CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of CVRx, Inc. (NASDAQ:CVRX) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $17.83.

CVRX has been the topic of several recent research reports. Piper Sandler boosted their price target on CVRx from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 5th. Craig Hallum boosted their target price on shares of CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. William Blair raised shares of CVRx from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 14th. Finally, Canaccord Genuity Group boosted their price objective on shares of CVRx from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, February 5th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. PDT Partners LLC bought a new stake in shares of CVRx in the 3rd quarter worth about $543,000. Centiva Capital LP bought a new stake in CVRx in the third quarter valued at about $178,000. Parkman Healthcare Partners LLC raised its stake in CVRx by 52.6% during the third quarter. Parkman Healthcare Partners LLC now owns 682,897 shares of the company’s stock valued at $6,016,000 after buying an additional 235,277 shares in the last quarter. State Street Corp lifted its holdings in CVRx by 11.4% during the 3rd quarter. State Street Corp now owns 264,733 shares of the company’s stock worth $2,332,000 after buying an additional 27,071 shares during the last quarter. Finally, Jane Street Group LLC grew its position in shares of CVRx by 36.1% in the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after acquiring an additional 5,053 shares in the last quarter. 75.27% of the stock is currently owned by institutional investors.

CVRx Price Performance

CVRx stock opened at $12.49 on Friday. The company has a quick ratio of 10.23, a current ratio of 12.06 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $325.19 million, a P/E ratio of -4.64 and a beta of 1.34. The firm has a fifty day moving average of $14.44 and a 200-day moving average of $12.64. CVRx has a 52-week low of $6.40 and a 52-week high of $21.04.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. As a group, analysts predict that CVRx will post -1.91 EPS for the current year.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.